Astrocytoma: Insights into Risk Factors, Pathogenesis, Diagnosis and Management

Ahmed M. Kabel^{1, 2,} , Kholoud Modais³, Arwa Salim³, Reham Ahmad³, Afrah Ahmad³ and Khaled A. Alnumari³

¹Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, Saudi Arabia

²Department of Pharmacology, Faculty of Medicine, Tanta University, Tanta, Egypt

³Pharm D, College of Pharmacy, Taif University, Taif, Saudi Arabia

Cite this paper:
Ahmed M. Kabel, Kholoud Modais, Arwa Salim, Reham Ahmad, Afrah Ahmad and Khaled A. Alnumari. Astrocytoma: Insights into Risk Factors, Pathogenesis, Diagnosis and Management. Journal of Cancer Research and Treatment. 2018; 6(3):70-73. doi: 10.12691/jcrt-6-3-2

Abstract

Astrocytoma is one of the most common types of brain tumors. It arises from astrocytes-star-shaped cells that make up the ¡°glue-like¡± or supportive tissue of the brain. There are different types and severities of Astrocytomas. According to (WHO),It can be classified into grades from I to IV. The most frequently diagnosed types of astrocytoma are pilocytic astrocytoma, grade II astrocytoma, anaplastic astrocytoma and glioblastoma multiforme. They may or may not be cancerous. The exact cause of astrocytoma is unknown. Astrocytomas occur slightly more often in men than in women. They are slightly more common in Caucasians. Astrocytomas can develop in both children and adults. The diagnosis of astrocytoma is based on a thorough clinical evaluation, characteristic physical findings, a careful patient history, and specialized tests. Astrocytomas may be treated with surgery, radiation therapy, chemotherapy or a combination of treatments.

Keywords:
Astrocytoma tumor pathogenesis diagnosis management

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Grimm SA, Chamberlain MC. Anaplastic astrocytoma. CNS Oncol 2016 Jul; 5(3): 145-57.
[2]	Bornhorst M, Frappaz D, Packer RJ. Pilocytic astrocytomas. Handb Clin Neurol 2016; 134: 329-44.
[3]	Pedersen CL, Romner B. Current treatment of low grade astrocytoma: a review. Clin Neurol Neurosurg 2013; 115(1): 1-8.
[4]	Bonfield CM, Steinbok P. Pediatric cerebellar astrocytoma: a review. Childs Nerv Syst 2015; 31(10): 1677-85.
[5]	Chourmouzi D, Papadopoulou E, Konstantinidis M, et al. Manifestations of pilocytic astrocytoma: a pictorial review. Insights into Imaging. 2014; 5(3): 387-402.
[6]	Gajavelli S, Nakhla J, Nasser R, Yassari R, Weidenheim KM, Graber J. Ollier disease with anaplastic astrocytoma: A review of the literature and a unique case. Surg Neurol Int 2016; 7(Suppl 23): S607-S611.
[7]	Caporalini C, Buccoliero AM, Scoccianti S, Moscardi S, Simoni A, Pansini L, et al. Granular cell astrocytoma: report of a case and review of the literature. Clin Neuropathol 2016; 35(4): 186-93.
[8]	Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastomamultiforme. Science 2008; 321(5897): 1807-12.
[9]	Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009 Dec 10. 462(7274): 739-44.
[10]	McLendon RE, Provenzale JM, Friedman AH. Anaplastic astrocytoma. McLendon RE, Rosenblum MK, Bigner DD, eds. Russell and Rubinstein's Pathology of Tumors of the Nervous System. 6th ed. London, UK: Edward Arnold; 2006. 75-89.
[11]	Dirven CM, Tuerlings J, Molenaar WM, Go KG, Louis DN. Glioblastomamultiforme in four siblings: a cytogenetic and molecular genetic study. J Neurooncol. 1995. 24(3): 251-8.
[12]	DeAngelis LM. Brain tumors. N Engl J Med 2001; 344: 114-23.
[13]	Louis DN, OhgakiH,Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007WHO classification of tumours of the central nervous system. ActaNeuropathol (Berl) 2007; 114: 97-109.
[14]	Hutter A, Schwetye KE, Bierhals AJ, McKinstry RC. Brain neoplasms: epidemiology, diagnosis, and prospects for cost-effective imaging. Neuroimaging Clin N Am 2003; 13: 237-50.
[15]	Bampoe J, Bernstein M. The role of surgery in low grade gliomas. J Neuro Oncol 1999; 42: 259-69.
[16]	Komori T. The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision. Neurol Med Chir (Tokyo) 2017; 57(7): 301-11.
[17]	Khatib ZA, Heideman RL, Kovnar EH, et al. Predominance of pilocytic histology in dorsally exophytic brain stem tumors. PediatrNeurosurg. 1994. 20(1): 2-10.
[18]	Fisher PG, Breiter SN, Carson BS, et al. A clinicopathologic reappraisal of brain stem tumor classification. Identification of pilocystic astrocytoma andfibrillary astrocytoma as distinct entities. Cancer. 2000 Oct 1. 89(7): 1569-76.
[19]	Reis GF, Tihan T. Practical molecular pathologic diagnosis of pilocyticastrocytomas. SurgPatholClin. 2015 Mar. 8 (1): 63-71.
[20]	Cummings TJ, Provenzale JM, Hunter SB, et al. Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis. ActaNeuropathol. 2000 May. 99(5): 563-70.
[21]	Bikowska-Opalach B, Szlufik S, Grajkowska W, Jozwiak J. Pilocytic astrocytoma: a review of genetic and molecular factors, diagnostic and prognostic markers. Histol Histopathol 2014; 29(10): 1235-48.
[22]	Atlas SW. Magnetic Resonance Imaging Of The Brain And Spine. Lippincott Williams & Wilkins. (2009) ISBN:078176985X.
[23]	Glantz M, Chamberlain M, Liu Q, Litofsky NS, Recht LD. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer. 2003 May 1. 97(9): 2262-6.
[24]	Scott J, Tsai YY, Chinnaiyan P, Yu HH. Effectiveness of radiotherapy for elderly patients with glioblastoma. Int J RadiatOncolBiol Phys. 2011 Sep 1. 81(1): 206-10. [Medline].
[25]	Malmstrom A, Gronberg BH, Marosi C, et al; Nordic Clinical Brain Tumour Study Group (NCBTSG). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012; 13(9): 916-26.
[26]	Forbes JA, Mobley BC, O'Lynnger TM, et al. Pediatric cerebellar pilomyxoid-spectrum astrocytomas: Report of 2 cases. J Neurosurg Pediatr 2011; 8(1): 90-6.
[27]	Ishkanian A, Laperriere NJ, Xu W, et al. Upfront observation versus radiation for adult pilocytic astrocytoma. Cancer. 2011 Sep 1. 117(17):4070-9
[28]	Khan MA, Godil SS, Tabani H, Panju SA, Enam SA. Clinical review of pediatric pilocytic astrocytomas treated at a tertiary care hospital in Pakistan. Surg Neurol Int 2012; 3:90.
[29]	MacDonald, T.B, MD, Packer.R.J,MD. Updated: Nov 25, 2014. Pediatric Astrocytoma Treatment & Management. In A Coppes. M.J (Ed) .Atlanta. Medscape
[30]	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System. Lyon, France: IARC Press; 2007.
[31]	Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004; 64(19): 6892-9.
[32]	McLendon RE, Friedman AH, Bruner J, Shah L, Gray L. Diffuse astrocytoma. McLendon RE, Rosenblum MK, Bigner DD, eds. Russell and Rubinstein's Pathology of Tumors of the Nervous System. 6th ed. London, UK: Edward Arnold; 2006. 57-74.
[33]	Theeler BJ, Ellezam B, Sadighi ZS, Mehta V, Tran MD, Adesina AM, et al. Adult pilocytic astrocytomas: clinical features and molecular analysis. J Neuroncol 2014; 16: 841-7.
[34]	Kabel AM, Abd Elmaaboud MA. Cancer: Role of Nutrition, Pathogenesis, Diagnosis and Management. Journal of Nutrition and Health 2014; 2(4): 48-51.